Atezolizumab Plus Bevacizumab vs Sorafenib for Unresectable Hepatocellular Carcinoma: Results From Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
Introduction The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab vs sorafenib as a first-line treatment in younger vs older patients with unrese...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2022-07-01
|
| Series: | Liver Cancer |
| Online Access: | https://beta.karger.com/Article/FullText/525671 |